You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium
Accession NumberDB01378
TypeSmall Molecule
GroupsNutraceutical
Description

Magnesium hydroxide is used primarily in “Milk of Magnesia”, a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.

Structure
Thumb
SynonymsNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number7439-95-4
WeightAverage: 24.305
Monoisotopic: 23.985041898
Chemical FormulaMg
InChI KeyJLVVSXFLKOJNIY-UHFFFAOYSA-N
InChI
InChI=1S/Mg/q+2
IUPAC Name
magnesium(2+) ion
SMILES
[Mg++]
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
KingdomInorganic compounds
Super ClassHomogeneous metal compounds
ClassHomogeneous alkaline earth metal compounds
Sub ClassNot Available
Direct ParentHomogeneous alkaline earth metal compounds
Alternative ParentsNot Available
Substituents
  • Homogeneous alkaline earth metal
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Insulin SignallingSignalingSMP00391
Excitatory Neural Signalling Through 5-HTR 7 and Serotonin SignalingSMP00311
Intracellular Signalling Through FSH Receptor and Follicle Stimulating HormoneSignalingSMP00333
Intracellular Signalling Through LHCGR Receptor and Luteinizing Hormone/ChoriogonadotropinSignalingSMP00338
Carnitine-acylcarnitine translocase deficiencyDiseaseSMP00517
Inositol Phosphate MetabolismMetabolicSMP00462
Phosphatidylinositol Phosphate MetabolismMetabolicSMP00463
Plasmalogen SynthesisMetabolicSMP00479
Corticotropin Activation of Cortisol ProductionSignalingSMP00310
Vasopressin Regulation of Water HomeostasisSignalingSMP00322
Adrenoleukodystrophy, X-linkedDiseaseSMP00516
Gemcitabine Metabolism PathwayDrug metabolismSMP00603
Tenofovir Metabolism PathwayDrug metabolismSMP00630
Joubert syndromeDiseaseSMP00582
Thioguanine Metabolism PathwayDrug metabolismSMP00647
Beta Oxidation of Very Long Chain Fatty AcidsMetabolicSMP00052
Gemcitabine Action PathwayDrug actionSMP00446
Excitatory Neural Signalling Through 5-HTR 6 and Serotonin SignalingSMP00312
Intracellular Signalling Through Histamine H2 Receptor and HistamineSignalingSMP00335
Muscle/Heart ContractionPhysiologicalSMP00588
Excitatory Neural Signalling Through 5-HTR 4 and SerotoninSignalingSMP00309
Adefovir Dipivoxil Metabolism PathwayDrug metabolismSMP00629
Alprenolol Action PathwayDrug actionSMP00297
Oxprenolol Action PathwayDrug actionSMP00304
Procainamide (Antiarrhythmic) Action PathwayDrug actionSMP00324
Flecainide Action PathwayDrug actionSMP00331
Labetalol Action PathwayDrug actionSMP00368
Amlodipine Action PathwayDrug actionSMP00376
Nisoldipine Action PathwayDrug actionSMP00381
Sotalol Action PathwayDrug actionSMP00660
Metipranolol Action PathwayDrug actionSMP00667
Atenolol Action PathwayDrug actionSMP00298
Penbutolol Action PathwayDrug actionSMP00305
Disopyramide Action PathwayDrug actionSMP00325
Ibutilide Action PathwayDrug actionSMP00332
Felodipine Action PathwayDrug actionSMP00377
Nitrendipine Action PathwayDrug actionSMP00382
Bopindolol Action PathwayDrug actionSMP00657
Epinephrine Action PathwayDrug actionSMP00661
Isoprenaline Action PathwayDrug actionSMP00663
Bevantolol Action PathwayDrug actionSMP00668
Bisoprolol Action PathwayDrug actionSMP00300
Metoprolol Action PathwayDrug actionSMP00302
Propranolol Action PathwayDrug actionSMP00307
Mexiletine Action PathwayDrug actionSMP00329
Nebivolol Action PathwayDrug actionSMP00366
Nifedipine Action PathwayDrug actionSMP00379
Dopamine Activation of Neurological Reward SystemSignalingSMP00308
Intracellular Signalling Through Prostacyclin Receptor and ProstacyclinSignalingSMP00354
Amiodarone Action PathwayDrug actionSMP00665
Bupranolol Action PathwayDrug actionSMP00670
Phenylacetate MetabolismMetabolicSMP00126
Betaxolol Action PathwayDrug actionSMP00299
Pindolol Action PathwayDrug actionSMP00306
Diltiazem Action PathwayDrug actionSMP00359
Isradipine Action PathwayDrug actionSMP00378
Intracellular Signalling Through PGD2 receptor and Prostaglandin D2SignalingSMP00343
Carteolol Action PathwayDrug actionSMP00658
Dobutamine Action PathwayDrug actionSMP00662
Arbutamine Action PathwayDrug actionSMP00664
Practolol Action PathwayDrug actionSMP00669
Acebutolol Action PathwayDrug actionSMP00296
Esmolol Action PathwayDrug actionSMP00301
Nadolol Action PathwayDrug actionSMP00303
Quinidine Action PathwayDrug actionSMP00323
Tocainide Action PathwayDrug actionSMP00330
Carvedilol Action PathwayDrug actionSMP00367
Verapamil Action PathwayDrug actionSMP00375
Nimodipine Action PathwayDrug actionSMP00380
Timolol Action PathwayDrug actionSMP00659
Levobunolol Action PathwayDrug actionSMP00666
Lamivudine Metabolism PathwayDrug metabolismSMP00649
Teniposide Action PathwayDrug actionSMP00443
Intracellular Signalling Through Adenosine Receptor A2a and AdenosineSignalingSMP00320
Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty AcidsMetabolicSMP00481
Fosphenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00326
Intracellular Signalling Through Adenosine Receptor A2b and AdenosineSignalingSMP00321
Fc Epsilon Receptor I Signaling in Mast CellsSignalingSMP00358
Teniposide Metabolism PathwayDrug metabolismSMP00602
Inositol MetabolismMetabolicSMP00011
Citric Acid CycleMetabolicSMP00057
Nucleotide Sugars MetabolismMetabolicSMP00010
Phospholipid BiosynthesisMetabolicSMP00025
Ethylmalonic EncephalopathyDiseaseSMP00181
Leukotriene C4 Synthesis DeficiencyDiseaseSMP00353
Globoid Cell LeukodystrophyDiseaseSMP00348
Etoposide Action PathwayDrug actionSMP00442
Carnitine palmitoyl transferase deficiency (II)DiseaseSMP00541
Mitochondrial complex II deficiencyDiseaseSMP00548
Glycogenosis, Type III. Cori disease, Debrancher glycogenosisDiseaseSMP00553
Glycogenosis, Type VI. Hers diseaseDiseaseSMP00555
Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1)DiseaseSMP00560
Fanconi-bickel syndromeDiseaseSMP00572
Glycogenosis, Type ICDiseaseSMP00574
Pentose Phosphate PathwayMetabolicSMP00031
Arachidonic Acid MetabolismMetabolicSMP00075
Glutaric Aciduria Type IDiseaseSMP00185
GluconeogenesisMetabolicSMP00128
Metachromatic Leukodystrophy (MLD)DiseaseSMP00347
Phenytoin (Antiarrhythmic) Action PathwayDrug actionSMP00327
HypophosphatasiaDiseaseSMP00503
Fabry diseaseDiseaseSMP00525
Medium chain acyl-coa dehydrogenase deficiency (MCAD)DiseaseSMP00542
2-ketoglutarate dehydrogenase complex deficiencyDiseaseSMP00549
Mucopolysaccharidosis VI. Sly syndromeDiseaseSMP00556
Glycogenosis, Type IBDiseaseSMP00573
Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty AcidsMetabolicSMP00482
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke DiseaseDiseaseSMP00374
Galactosemia II (GALK)DiseaseSMP00495
Sulfite oxidase deficiencyDiseaseSMP00532
Long chain acyl-CoA dehydrogenase deficiency (LCAD)DiseaseSMP00539
Congenital lactic acidosisDiseaseSMP00546
Pyruvate dehydrogenase deficiency (E2)DiseaseSMP00551
Triosephosphate isomeraseDiseaseSMP00563
Etoposide Metabolism PathwayDrug metabolismSMP00601
Valproic Acid Metabolism PathwayDrug metabolismSMP00635
Phytanic Acid Peroxisomal OxidationMetabolicSMP00450
Vitamin B6 MetabolismMetabolicSMP00017
Ribose-5-phosphate isomerase deficiencyDiseaseSMP00519
Butyrate MetabolismMetabolicSMP00073
Sulfate/Sulfite MetabolismMetabolicSMP00041
Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency)DiseaseSMP00235
Refsum DiseaseDiseaseSMP00451
GlycolysisMetabolicSMP00040
Lidocaine (Antiarrhythmic) Action PathwayDrug actionSMP00328
Krabbe diseaseDiseaseSMP00526
Glycogenosis, Type VII. Tarui diseaseDiseaseSMP00531
Carnitine palmitoyl transferase deficiency (I)DiseaseSMP00538
Trifunctional protein deficiencyDiseaseSMP00545
Pyruvate dehydrogenase deficiency (E3)DiseaseSMP00550
Sucrase-isomaltase deficiencyDiseaseSMP00557
Fructose-1,6-diphosphatase deficiencyDiseaseSMP00562
Glycogenosis, Type IA. Von gierke diseaseDiseaseSMP00581
Glucose-6-phosphate dehydrogenase deficiencyDiseaseSMP00518
Galactosemia IIIDiseaseSMP00496
Very-long-chain acyl coa dehydrogenase deficiency (VLCAD)DiseaseSMP00540
Fumarase deficiencyDiseaseSMP00547
Glycogen synthetase deficiencyDiseaseSMP00552
Glycogenosis, Type IV. Amylopectinosis, Anderson diseaseDiseaseSMP00554
Fatty acid MetabolismMetabolicSMP00051
Riboflavin MetabolismMetabolicSMP00070
Sphingolipid MetabolismMetabolicSMP00034
Starch and Sucrose MetabolismMetabolicSMP00058
Oxidation of Branched Chain Fatty AcidsMetabolicSMP00030
Gaucher DiseaseDiseaseSMP00349
Transaldolase deficiencyDiseaseSMP00520
Betaine MetabolismMetabolicSMP00123
Folate MetabolismMetabolicSMP00053
Steroid BiosynthesisMetabolicSMP00023
Chondrodysplasia Punctata II, X Linked Dominant (CDPX2)DiseaseSMP00388
Piroxicam Action PathwayDrug actionSMP00077
Rofecoxib Action PathwayDrug actionSMP00087
Alendronate Action PathwayDrug actionSMP00095
Nicotinate and Nicotinamide MetabolismMetabolicSMP00048
HypercholesterolemiaDiseaseSMP00209
Naproxen Action PathwayDrug actionSMP00120
Lovastatin Action PathwayDrug actionSMP00099
Cerivastatin Action PathwayDrug actionSMP00111
Meloxicam Action PathwayDrug actionSMP00106
Hyper-IgD syndromeDiseaseSMP00509
Congenital disorder of glycosylation CDG-IIdDiseaseSMP00579
Antrafenine Action PathwayDrug actionSMP00693
Magnesium salicylate Action PathwayDrug actionSMP00698
Tiaprofenic Acid Action PathwayDrug actionSMP00705
Acetaminophen Action PathwayDrug actionSMP00710
Fructose intolerance, hereditaryDiseaseSMP00725
Fructose and Mannose DegradationMetabolicSMP00064
Spermidine and Spermine BiosynthesisMetabolicSMP00445
Lactose SynthesisMetabolicSMP00444
Lysosomal Acid Lipase Deficiency (Wolman Disease)DiseaseSMP00319
Ibandronate Action PathwayDrug actionSMP00079
Pravastatin Action PathwayDrug actionSMP00089
Celecoxib Action PathwayDrug actionSMP00096
Tay-Sachs DiseaseDiseaseSMP00390
Sialuria or French Type SialuriaDiseaseSMP00217
Suprofen Action PathwayDrug actionSMP00101
Indomethacin Action PathwayDrug actionSMP00104
Diflunisal Action PathwayDrug actionSMP00289
Risedronate Action PathwayDrug actionSMP00112
Valdecoxib Action PathwayDrug actionSMP00116
Mevalonic aciduriaDiseaseSMP00510
FructosuriaDiseaseSMP00561
GLUT-1 deficiency syndromeDiseaseSMP00580
Antipyrine Action PathwayDrug actionSMP00692
Carprofen Action PathwayDrug actionSMP00694
Lumiracoxib Action PathwayDrug actionSMP00699
Tenoxicam Action PathwayDrug actionSMP00706
GalactosemiaDiseaseSMP00182
Oxaprozin Action PathwayDrug actionSMP00113
Fluvastatin Action PathwayDrug actionSMP00119
G(M2)-Gangliosidosis: Variant B, Tay-sachs diseaseDiseaseSMP00534
Fenoprofen Action PathwayDrug actionSMP00696
Phenylbutazone Action PathwayDrug actionSMP00701
Trisalicylate-choline Action PathwayDrug actionSMP00703
Salicylate-sodium Action PathwayDrug actionSMP00708
Amino Sugar MetabolismMetabolicSMP00045
CHILD SyndromeDiseaseSMP00387
Sialuria or French Type SialuriaDiseaseSMP00216
Acetylsalicylic Acid Action PathwayDrug actionSMP00083
Ketoprofen Action PathwayDrug actionSMP00085
Diclofenac Action PathwayDrug actionSMP00093
Galactose MetabolismMetabolicSMP00043
Cholesteryl ester storage diseaseDiseaseSMP00508
Mercaptopurine Metabolism PathwayDrug metabolismSMP00609
Flurbiprofen Action PathwayDrug actionSMP00697
Nepafenac Action PathwayDrug actionSMP00702
Tolmetin Action PathwayDrug actionSMP00704
Salicylic Acid Action PathwayDrug actionSMP00709
Folate malabsorption, hereditaryDiseaseSMP00724
DesmosterolosisDiseaseSMP00386
Salla Disease/Infantile Sialic Acid Storage DiseaseDiseaseSMP00240
Etodolac Action PathwayDrug actionSMP00084
Ibuprofen Action PathwayDrug actionSMP00086
Sulindac Action PathwayDrug actionSMP00094
Nabumetone Action PathwayDrug actionSMP00114
Methotrexate Action PathwayDrug actionSMP00432
Zoledronate Action PathwayDrug actionSMP00107
Atorvastatin Action PathwayDrug actionSMP00131
Canavan DiseaseDiseaseSMP00175
Tyrosinemia Type 2 (or Richner-Hanhart syndrome)DiseaseSMP00369
Smith-Lemli-Opitz Syndrome (SLOS)DiseaseSMP00389
Simvastatin Action PathwayDrug actionSMP00082
Rosuvastatin Action PathwayDrug actionSMP00092
Ketorolac Action PathwayDrug actionSMP00098
Bromfenac Action PathwayDrug actionSMP00102
Mefenamic Acid Action PathwayDrug actionSMP00109
Pamidronate Action PathwayDrug actionSMP00117
Wolman diseaseDiseaseSMP00511
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00543
Etoricoxib Action PathwayDrug actionSMP00695
Lornoxicam Action PathwayDrug actionSMP00700
Salsalate Action PathwayDrug actionSMP00707
HypoacetylaspartiaDiseaseSMP00192
PhenylketonuriaDiseaseSMP00206
Tyrosinemia Type 3 (TYRO3)DiseaseSMP00370
Primary hyperoxaluria II, PH2DiseaseSMP00558
Warburg EffectMetabolicSMP00654
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)DiseaseSMP00334
Pyruvate kinase deficiencyDiseaseSMP00559
Ammonia RecyclingMetabolicSMP00009
Phenylalanine and Tyrosine MetabolismMetabolicSMP00008
Pyruvate MetabolismMetabolicSMP00060
Pyruvate Dehydrogenase Complex DeficiencyDiseaseSMP00212
HypermethioninemiaDiseaseSMP00341
Tyrosinemia Type IDiseaseSMP00218
Beta Ureidopropionase DeficiencyDiseaseSMP00172
Succinic semialdehyde dehydrogenase deficiencyDiseaseSMP00567
Aspartate MetabolismMetabolicSMP00067
Leigh SyndromeDiseaseSMP00196
Methionine MetabolismMetabolicSMP00033
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
UMP Synthase Deiciency (Orotic Aciduria)DiseaseSMP00219
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)DiseaseSMP00202
Dopamine beta-hydroxylase deficiencyDiseaseSMP00498
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase DeficiencyDiseaseSMP00243
AlkaptonuriaDiseaseSMP00169
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Tyrosine MetabolismMetabolicSMP00006
Glutamate MetabolismMetabolicSMP00072
Hyperinsulinism-Hyperammonemia SyndromeDiseaseSMP00339
2-Hydroxyglutric Aciduria (D And L Form)DiseaseSMP00136
Monoamine oxidase-a deficiency (MAO-A)DiseaseSMP00533
Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
HawkinsinuriaDiseaseSMP00190
Molybdenum Cofactor DeficiencyDiseaseSMP00203
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
SarcosinemiaDiseaseSMP00244
Hyperglycinemia, non-ketoticDiseaseSMP00485
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Glycine N-methyltransferase DeficiencyDiseaseSMP00222
Pyrimidine MetabolismMetabolicSMP00046
Dihydropyrimidinase DeficiencyDiseaseSMP00178
Tyrosinemia, transient, of the newbornDiseaseSMP00494
HomocarnosinosisDiseaseSMP00385
Adenosine Deaminase DeficiencyDiseaseSMP00144
AICA-RibosiduriaDiseaseSMP00168
Glycine and Serine MetabolismMetabolicSMP00004
Thioguanine Action PathwayDrug actionSMP00430
Disulfiram Action PathwayDrug actionSMP00429
Myoadenylate deaminase deficiencyDiseaseSMP00537
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
Mercaptopurine Action PathwayDrug actionSMP00428
Xanthinuria type IDiseaseSMP00512
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00484
Xanthinuria type IIDiseaseSMP00513
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
3-Phosphoglycerate dehydrogenase deficiencyDiseaseSMP00721
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
Purine MetabolismMetabolicSMP00050
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
Non Ketotic HyperglycinemiaDiseaseSMP00223
Azathioprine Action PathwayDrug actionSMP00427
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9176
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8824
CYP450 2C9 substrateNon-inhibitor0.9221
CYP450 2D6 substrateNon-inhibitor0.9555
CYP450 2C19 substrateNon-inhibitor0.9469
CYP450 3A4 substrateNon-inhibitor0.9846
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.6381
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point651 °CPhysProp
boiling point1100 °CPhysProp
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, “Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet.” U.S. Patent US4151013, issued 0000.

US4151013
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 28:08.04.24
  • 28:12.92
  • 40:12.00
  • 40:34.00*
  • 56:04.00
  • 56:12.00
  • 84:24.00
  • 84:92.00
  • 88:29.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Sodium/potassium-transporting ATPase subunit alpha-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sodium/potassium-transporting ATPase subunit alpha-1 P05023 Details

References:

  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields] Biofizika. 2006 May-Jun;51(3):545-52. Pubmed
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. Pubmed
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. Pubmed
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. Pubmed

Comments
comments powered by Disqus
Drug created on July 06, 2007 14:30 / Updated on March 14, 2014 14:52